Cover Image
市場調查報告書

持續血糖檢測系統的全球市場 - 2014∼2021年的市場機會及市場預測

World Continuous Glucose Monitoring Systems - Market Opportunities and Forecasts, 2014 - 2021

出版商 Allied Market Research 商品編碼 335355
出版日期 內容資訊 英文 118 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
持續血糖檢測系統的全球市場 - 2014∼2021年的市場機會及市場預測 World Continuous Glucose Monitoring Systems - Market Opportunities and Forecasts, 2014 - 2021
出版日期: 2015年06月01日 內容資訊: 英文 118 Pages
簡介

持續血糖檢測系統 (CGMS)是糖尿病管理領域的最新技術之一,今後預測將引進到智慧手機、穿戴式設備連動的CGMS等高科技CGMS及非侵入式CGMS,甚至智慧型糖尿病管理解決方案之人工生物工學胰臟的登場等廣泛市場。在這樣的背景下CGMS全球市場預測從2014年到2021年間將以年複合成長率(CAGR)31.4%的速度急速擴大,到2021年前達到29億美金的規模。

本報告詳查CGMS的全球市場,提供您推動市場成長要素,阻礙因素,新技術,市場機會,重要的策略等,到目前市場方案分析與2021年前的市場預測。該市場可依CGMS的結構品,終端用戶領域,年齡層,以及地區別加以分類,本報告基於各分類提供更細分的市場分析與未來預測。同時更提供這個市場上主要企業包含業績,策略,以及最近的企業發展和SWOT分析之詳細企業簡介。

第1章 序論

  • 關於本報告
  • 主要的成果
  • 主要市場領域
  • 調查手法

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 血糖檢測系統的必要性
    • 糖尿病全球的流行
      • 第一型糖尿病
      • 第二型糖尿病
      • 前糖尿病狀態與妊娠糖尿病 (GDM)
      • 次發性糖尿病
    • 糖尿病的全球醫療費用支出
  • CGMS的新技術
    • 智慧型手機連接型CGMS
    • 穿戴式設備及智慧型手機連接型CGMS
    • 非侵入性CGMS
    • 研究開發中的侵入性CGMS
    • 智慧糖尿病管理解決方案 Bionic Pancreas (生物工學人工胰臟)
  • CGMS - 重病終端用戶領域
    • 加護病房(ICU)上,CGMS的迫切重要性
      • 加護病房經常發生的壓力性高血糖症
      • 加護病房裡不合乎標準的錯誤血糖管理
  • 加護病房上CGMS的優點與促使CGMS引進的要素
    • CGMS可支援在ICU中嚴密的血糖控制
    • 伴隨CGMS使用的成本優勢
    • POC血糖儀在ICU上效率性比CGMS低
    • ICU的職員偏好CGMS
  • 重要的調查結果
    • 左右市場的最重要要素
    • 最重要投資領域
    • 為求勝出的最重要策略
  • 價值鏈分析
  • 市場佔有率分析 - 2014年
  • 政府法規
  • 保險給付方案
  • 推動市場成長要素
    • 糖尿病的全球性增加
    • 原本就比POC血糖儀更具優勢,預測今後市場將日益成長
    • 新興各國和初步開發國的認知度提升
    • 針對新終端用戶領域的OTC/POC CGMS的開發重點化-未來市場成長
    • 美食品藥物管理局(FDA)的Bionic Pancreas的認證將促進未來市場成長
  • 阻礙市場成長要素
    • 嚴格的法律規章要件
    • 保險給付制度不足會成為CGMS引進的障礙
    • 準確度與成本等會成為繼續使用CGMS的障礙
  • 市場機會
    • ICU的CGMS的高引進率
    • OTC/POC CGMS -產品的用途/使用範圍的擴大
    • 未診斷的患者數
  • 國際企業為了打入新興國家市場所用的策略
    • 為了快速打入亞太地區市場和LAMEA (南美·中東·非洲)市場而取得CE認証
    • 為了強化地區性銷售網而在流通上建立企業合作
    • 針對用戶提升知名度,還有推出具有競爭力的產品價格

第4章 從按結構品來看的持續血糖檢測系統全球市場

  • 單體型及整合型CGM系統
    • 市場規模及未來預測
  • 感測器
    • 主要市場趨勢
      • 非侵入型血糖感測器
      • 皮下感測器 (微創感測器)
      • 傳統技術 - Holter類型及資料總計分析感測器
      • 新技術 - 即時感測器
    • 主要的推動市場成長要素及市場機會
    • 市場規模及未來預測
  • 傳送器及接收器
    • 主要市場趨勢
    • 主要的推動市場成長要素及市場機會
    • 市場規模及未來預測
  • 整合化胰島素幫浦
    • 概要
    • 主要市場趨勢
    • 主要的推動市場成長要素及市場機會
    • 市場規模及未來預測

第5章 各終端用戶領域中的持續血糖檢測系統全球市場

  • 市場規模及未來預測
  • 診斷中心/醫院
    • 市場規模及未來預測
  • ICU
    • 市場規模及未來預測
  • 家庭·醫療保健
    • 市場規模及未來預測

第6章 從各年齡層來看的持續血糖檢測系統全球市場

  • 未成年者
  • X世代
  • 老人醫療 / 未診斷患者

第7章 從各地區市場來看的持續血糖檢測系統全球市場

  • 北美
    • 市場規模及未來預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 主要市場趨勢
    • 主要的推動市場成長要素及市場機會
    • 法國
    • 德國
    • 英國
    • 其他歐洲各國
  • 亞太地區
    • 市場規模及未來預測
    • 印度
    • 澳洲
    • 中國
    • 其他的亞太地區各國
  • 南美,中東,及非洲 (LAMEA) 地區
    • 概要
    • 市場規模及未來預測
    • 波灣合作理事會 (GCC)

第8章 企業簡介

  • Medtronic Plc.
    • 公司概要
    • 商務業績
    • 策略性動向和企業發展
    • SWOT分析
  • Dexcom Inc.
  • Abbott Diabetic Care (Abbott Laboratories)
  • Animas Corporation
  • Echo Therapeutics
  • Insulet Corporation
  • Glysens Inc.
  • Senseonics, Inc.
目錄
Product Code: LI 15692

Title: World Continuous Glucose Monitoring Systems Market by Components (Sensors, Transmitters & Receivers, Integrated insulin pumps), Customer Segments (Diagnostics, ICUs, Home Healthcare) and End-user Demographics (Juveniles, Gen X, Geriatrics) - Global Opportunity Analysis and Industry Forecast, 2014 - 2021.

Continuous Glucose Monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM systems are a type of glucose monitoring devices that function by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in the interstitial fluid or in the blood and results are transmitted via a transmitter to a receiver/monitor that displays the results. CGM systems have emerged as an integral part of diabetes management owing to its several advantages over other glucose monitoring devices. Unlike conventional glucose monitors, these systems enable periodic monitoring of glucose levels, which is crucial to avoid any diabetic complications. In addition, CGMS technology has laid a roadmap to the most awaited, high-tech, closed-loop ‘artificial/bionic pancreas'. Therefore, developing novel and technologically advanced CGMS is the prime focus of several glucose monitoring device manufacturing companies. CGMS offer a wide range of applications across all age-cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs and home healthcare) and geographies. Thus, CGMS market shows lucrative opportunity for both CGMS manufacturers and insulin pump manufacturers.

The global CGMS market is forecast to reach $2.9 billion by 2021 registering a CAGR of 31.4% over the forecast period. The pipeline of high-tech CGMS devices, such as smartphone-connected CGMS, wearable and smartphone-connected CGMS, non-invasive CGMS and ‘smart' diabetes management solution (also called artificial/bionic pancreas), would result in larger adoption of CGMS among endocrinologists and patients.

The market is categorized based on components, customer segments, end-user demographics and geographic regions. The CGMS components market includes durable components such as transmitters & receivers and integrated insulin pumps; and disposable components such as sensors. The segment for sensors occupies a dominant share in the CGMS market primarily due to the recurring sales of CGMS, short scrap life and bulk purchases. CGMS are deployed primarily by the diagnostic centers/clinics. Moreover, increasing usage of CGMS across the hospital ICUs and in-home healthcare settings has been observed. The CGMS devices market by age demographics is categorized as juveniles, Gen X and geriatrics.

Detailed geographical analysis and segmentation is provided at country-level per-region-North America (U.S., Canada and Mexico), Europe (U.K., France, Germany and others), Asia-Pacific (India, China and Australia) and LAMEA (Gulf Cooperation Council). Key market players include Medtronic plc, Dexcom, Inc., Abbott Diabetes Care, Animas Corporation, including others. The major strategies adopted by the market players across geographies are collaborations, product launches and approvals. Collaborations in the regions focus on innovation, distribution and commercialization of the devices.

KEY BENEFITS

  • In-depth and country-level analysis within all the geographic regions would provide a clear understanding of current and future trends in the CGMS market
  • Comprehensive analysis of factors that drive and restrict the growth of the CGMS market is provided
  • The report covers detailed quantitative analysis of the current market and estimations through 2014-2021, which would enable the stakeholders to capitalize on prevailing market opportunities
  • A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
  • An in-depth analysis of current research and clinical developments within CGMS market is provided with key market dynamic factors that help in understanding the behavior of market
  • Key market players within the CGMS market are profiled in the report and their strategies are analyzed thoroughly, which help in understanding the competitive outlook of the global CGMS market

KEY MARKET SEGMENTS

The CGMS market is segmented based on components, customer segments, end-user demographics and geography (country-level).

Global CGMS Market - by Components

  • Sensors
  • Transmitters & Receivers
  • Integrated insulin pumps

Global CGMS Market - by Customer Segments

  • Diagnostics/Clinic
  • ICUs
  • Home Healthcare

Global CGMS Market - by End-user Demographics

  • Juveniles
  • Gen X
  • Geriatrics/undiagnosed

Global CGMS Market - by Geography

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Others
  • Asia-Pacific
    • China
    • India
    • Australia
    • Others
  • LAMEA
  • Gulf Cooperation Council (GCC)
  • Others

Table of Contents

Chapter 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segment
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

Chapter 2: EXECUTIVE SUMMARY

Chapter 3: MARKET OVERVIEW

  • 3.1. Market definition
  • 3.2. Need for glucose monitoring systems
    • 3.2.1. Diabetes a pandemic
      • 3.2.1.1. Type 1 diabetes
      • 3.2.1.2. Type-2 diabetes
      • 3.2.1.3. Pre-diabetes and Gestational Diabetes Mellitus (GDM)
      • 3.2.1.4. Gestational Diabetes Mellitus (GDM)
      • 3.2.1.5. Secondary diabetes
    • 3.2.2. Global healthcare expenditure on diabetes
  • 3.3. Emerging technologies in CGMS
    • 3.3.1. Smartphone-connected CGMS
    • 3.3.2. Wearable and smartphone-connected CGMS
    • 3.3.3. Non-invasive CGMS
    • 3.3.4. Invasive CGMS in the R&D pipeline
    • 3.3.5. 'Smart diabetes management solution Bionic Pancreas
  • 3.4. CGMS - Prime end user segments
    • 3.4.1. CGMS crucial need in Intensive Care Units (ICUs)
      • 3.4.1.1. Stress Hyperglycemia common occurrence in ICUs
    • 3.4.1.2. Non-standardization and erroneous glycemic control across ICUs
    • 3.4.2. Benefits and factors driving adoption of CGMS in ICUs
      • 3.4.2.1. CGMS aid in Tight Glycemic Control in ICUs
      • 3.4.2.2. Cost benefits from usage of CGMS
      • 3.4.2.3. POC Glucometers less effective in ICUs - as compared to CGMS
      • 3.4.2.4. CGMS most preferred by ICU staff
  • 3.5. Key findings
    • 3.5.1. Top impacting factors
    • 3.5.2. Top investment pockets
      • 3.5.2.1. CGMS market By End User Segments
      • 3.5.2.2. CGMS market by geography
    • 3.5.3. Top winning strategies
  • 3.6. Value chain analysis
  • 3.7. Market share analysis, 2014
  • 3.8. Government regulations
  • 3.9. Reimbursement scenario
  • 3.10. Drivers
    • 3.10.1. Rise in incidence of diabetes globally
    • 3.10.2. Inherent benefits of CGMS over POC glucometers drive market growth
    • 3.10.3. Increase in awareness in developing and underdeveloped economies
    • 3.10.4. Focus on developing OTC/POC CGMS catering to new end user segment - future growth driver
    • 3.10.5. FDA, U.S. approval of Bionic Pancreas future growth driver
  • 3.11. Restraints
    • 3.11.1. Stringent regulatory requirements
    • 3.11.2. Inadequate reimbursements a barrier in CGMS adoption
    • 3.11.3. Accuracy and cost a hindrance in continuing use of CGMS
  • 3.12. Opportunities
    • 3.12.1. Higher adoption rate of CGMS in ICUs
    • 3.12.2. OTC/POC CGMS - expanded product applications/usage
    • 3.12.3. Undiagnosed patient population
  • 3.13. Winning strategies for MNCs for entering emerging markets
    • 3.13.1. Gaining CE approvals for a speedier entry into Asia--Pacific and LAMEA markets
    • 3.13.2. Forming distribution alliances to enhance geographical reach
    • 3.13.3. Raising end-user awareness and competitive product pricing

Chapter 4: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY COMPONENTS

  • 4.1. Stand-alone and Integrated CGM systems
    • 4.1.1. Market size and forecast
  • 4.2. Sensors
    • 4.2.1. Key market trends
      • 4.2.1.1. Non-invasive glucose sensors
      • 4.2.1.2. Subcutaneous sensors (Minimally Invasive Sensors)
      • 4.2.1.3. Conventional technology holter-yype retrospective sensors
      • 4.2.1.4. Advanced technology Real-Time sensors
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. Transmitters & Receivers
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. Integrated Insulin pumps
    • 4.4.1. Overview
    • 4.4.2. Key market trends
    • 4.4.3. Key growth factors and opportunities
    • 4.4.4. Market size and forecast

Chapter 5: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET - BY END USER SEGMENT

  • 5.1. Market size and forecast
  • 5.2. Diagnostic centers/clinics
    • 5.2.1. Market size and forecast
  • 5.3. ICUs
    • 5.3.1. Market size and forecast
  • 5.4. Home healthcare
    • 5.4.1. Market size and forecast

Chapter 6: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET BY AGE DEMOGRAPHICS

  • 6.1. Juveniles
  • 6.2. Gen X
  • 6.3. Geriatrics / undiagnosed

Chapter 7: CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET- BY GEOGRAPHY

  • 7.1. North America
    • 7.1.1. Market size and forecast
    • 7.1.2. U.S.
    • 7.1.3. Canada
    • 7.1.4. Mexico
  • 7.2. Europe
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.4. France
      • 7.2.4.1. Key market trends
      • 7.2.4.2. Key growth factors and opportunities
    • 7.2.5. Germany
      • 7.2.5.1. Key market trends
      • 7.2.5.2. Key growth factors and opportunities
    • 7.2.6. U.K.
      • 7.2.6.1. Key market trends
      • 7.2.6.2. Key growth factors and opportunities
    • 7.2.7. Other European countries
  • 7.3. Asia-Pacific
    • 7.3.1. Market size and forecast
    • 7.3.2. India
      • 7.3.2.1. Key market trends
    • 7.3.3. Australia
      • 7.3.3.1. Key market trends
    • 7.3.4. China
      • 7.3.4.1. Key market trends
    • 7.3.5. Other APAC countries
  • 7.4. LAMEA
    • 7.4.1. Overview
    • 7.4.2. Market size and forecast
    • 7.4.3. Gulf Cooperation Council (GCC)
      • 7.4.3.1. Key market trends

Chapter 8: COMPANY PROFILES

  • 8.1. Medtronic Plc.
    • 8.1.1. Company overview
    • 8.1.2. Business performance
    • 8.1.3. Strategic moves and developments
      • 8.1.3.1. Principal strategies: product launch
      • 8.1.3.2. Secondary strategies: approval
      • 8.1.3.3. Other strategies: strategic alliance and collaboration
    • 8.1.4. SWOT analysis of Medtronic Plc
  • 8.2. Dexcom Inc.
    • 8.2.1. Company overview
    • 8.2.2. Business performance
    • 8.2.3. Strategic moves and developments
      • 8.2.3.1. Principal strategies: agreement/partnership
      • 8.2.3.2. Secondary strategies: approval
      • 8.2.3.3. Other strategies: acquisition
    • 8.2.4. SWOT analysis of Dexcom
  • 8.3. Abbott Diabetic Care (Abbott Laboratories)
    • 8.3.1. Company overview
    • 8.3.2. Business performance
    • 8.3.3. Strategic moves and developments
    • 8.3.4. SWOT analysis of Abbott diabetic care
  • 8.4. Animas Corporation
    • 8.4.1. Company overview
    • 8.4.2. Strategic moves and developments
    • 8.4.3. SWOT analysis of Animas Corporation
  • 8.5. Echo Therapeutics
    • 8.5.1. Company Overview
    • 8.5.2. Strategic moves and development
    • 8.5.3. SWOT Analysis of Echo Therapeutics
  • 8.6. Insulet Corporation
    • 8.6.1. Company overview
    • 8.6.2. Strategic moves and developments
    • 8.6.3. SWOT analysis of INSULET Corporation
  • 8.7. Glysens Inc.
    • 8.7.1. Company overview
    • 8.7.2. Strategic moves and developments
    • 8.7.3. SWOT Analysis of Glysens Inc.
  • 8.8. Senseonics, Inc.
    • 8.8.1. Company overview
    • 8.8.2. Strategic moves and development
    • 8.8.3. SWOT analysis of Senseonics, Inc.

List of Tables

  • TABLE 1: FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2014)
  • TABLE 2: FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2013)
  • TABLE 3: GLOBAL CGM MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 4: GLOBAL CGM SENSORS MARKET BY GEOGRAPHY, 2014 2021 ($MILLION)
  • TABLE 5: GLOBAL CGM TRANSMITTERS AND RECEIVERS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 6: GLOBAL CGM INTEGRATED INSULIN PUMPS MARKET BY GEOGRAPHY, 2014 2021 ($MILLION)
  • TABLE 7: GLOBAL CGM MARKET BY END USER SEGMENT, 2014-2021 ($MILLION)
  • TABLE 8: GLOBAL CGM DIAGNOSTIC CENTRES/CLINICS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 9: GLOBAL CGM ICUS MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 10: GLOBAL CGM HOME HEALTHCARE MARKET BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 11: TYPE-1 DIABETES (0-14 YEARS), 2013
  • TABLE 12: FACTORS IMPACTING GEOGRAPHICAL REGIONS IN 2014 AND 2021
  • TABLE 13: GLOBAL CGMS BY GEOGRAPHY, 2014-2021 ($MILLION)
  • TABLE 14: NORTH AMERICA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
  • TABLE 15: NORTH AMERICA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 16: PREVALENCE ESTIMATES OF DIABETES (20-79 YEARS), 2013, EUROPE
  • TABLE 18: EUROPE CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 19: TOP 10 COUNTRIES WITH DIABETES INCIDENCE 2013 AND 2035
  • TABLE 20: PREVALENCE ESTIMATES OF DIABETES, 2013 AND 2035
  • TABLE 21: APAC CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
  • TABLE 22: APAC CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 23: MEDICAL DEVICES USED IN AUSTRALIA
  • TABLE 24: LAMEA CGMS MARKET BY COUNTRIES, 2014-2021 ($MILLION)
  • TABLE 25: LAMEA CGMS MARKET BY COMPONENTS, 2014-2021 ($MILLION)
  • TABLE 26: MEDTRONIC BUSINESS SNAPSHOT
  • TABLE 27: MEDTRONIC REVENUE BY BUSINESS UNITS (2014)
  • TABLE 28: DEXCOM INC. BUSINESS SNAPSHOT
  • TABLE 29: ABBOTT DIABETIC CAREBUSINESS SNAPSHOT
  • TABLE 30: ANIMAS CORPORATION BUSINESS SNAPSHOT
  • TABLE 31: ECHO THERAPEUTICS COMPANY SNAPSHOT
  • TABLE 32: INSULET CORPORATION BUSINESS SNAPSHOT
  • TABLE 33: GLYSENS INC. BUSINESS SNAPSHOT
  • TABLE 34: SENSEONICS, INC. SNAPSHOT

List of Figures

  • FIG. 1: PREVALENCE OF TYPE 1 DIABETES (AGED <15 YEARS), BY GEOGRAPHY
  • FIG. 2: GLOBAL PREVALENCE OF TYPE-2 DIABETES (2000) AND ESTIMATED PREVALENCE (2030)
  • FIG. 3: PREDISPOSITION AND RISK FACTORS SIMILAR FOR PRE-DIABETES AND TYPE-2 DIABETES
  • FIG. 4: GLOBAL FINANCIAL BURDEN OF DIABETES ATTRIBUTED TO AGE GROUP (20 79 YEARS)
  • FIG. 5: GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
  • FIG. 6: OCCURENCE OF HYPERGLYCEMIA IN ICUS
  • FIG. 7: TOP FACTORS IMPACTING CGMS MARKET, 2014-2021
  • FIG. 8 : OP INVESTMENT POCKETS IN CGMS END USER SEGMENT MARKETS
  • FIG. 9 : OP INVESTMENT POCKETS IN CGMS GEOGRAPHY MARKETS
  • FIG. 10: TOP WINNING STRATEGIES IN CGMS MARKET, 2010 - 2014
  • FIG. 11: TOP WINNING STRATEGY IN CGMS MARKET BY YEAR, 2010 2014 (SEPTEMBER)
  • FIG. 13: MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET 2014
  • FIG. 14: GLOBAL INCIDENCE OF DIABETES, BY GEOGRAPHY (2000, 2011 AND 2030)
  • FIG. 15: PATIENT POPULATION UNDIAGNOSED FOR DIABETES , 2013 (MILLION)
  • FIG. 16: GLOBAL CGMS MARKET BY END-USER DEMOGRAPHICS, 2014 AND 2021
  • FIG. 17: CASES OF DIABETES BY AGE GROUP IN NORTH AMERICA (1,000S) (2013)
  • FIG. 18: CASES OF DIABETES BY AGE GROUP IN EUROPE (1,000S) (2013)
  • FIG. 19: MEDTRONIC REVENUE BY GEOGRAPHY (2014)
  • FIG. 20: SWOT ANALYSIS OF MEDTRONIC PLC
  • FIG. 21: SWOT ANALYSIS OF DEXCOM INC.
  • FIG. 22: REVENUE BY BUSINESS SEGMENT (2014)
  • FIG. 23: SWOT ANALYSIS OF ABBOTT DIABETIC CARE
  • FIG. 24: SWOT ANALYSIS OF ANIMAS CORPORATION
  • FIG. 25: SWOT ANALYSIS OF ECHO THERAPEUTICS
  • FIG. 26: SWOT ANALYSIS OF INSULET CORPORATION
  • FIG. 27: SWOT ANALASIS OF GLYSEN INCORPORATED
  • FIG. 28: SWOT ANALYSIS OF SENSEONICS, INC.
Back to Top